US › Healthcare

Fate Therapeutics Inc (FATE)

US · Healthcare · Biotechnology

$1.83-0.81%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$2.1M

Revenue YoY

+9.2%

Net profit

$-30.2M

EPS

$-0.25

EPS estimate

$-0.28

Net margin

-1,448.6%

EPS came in at -0.25 against a street estimate of -0.28 — a beat of 10.7%.

Key statistics

Market cap

$221.7M

Forward P/E

0.0

P/B

1.60

Book value

$1.31

EPS (TTM)

$-0.93

52-week high

$3.23

52-week low

$0.95

50-day MA

$2.27

200-day MA

$1.97

Beta

2.67

Analyst view

Analysts rate Fate Therapeutics Inc a buy (5 buy, 6 hold, 0 sell out of 11) with an average price target of $5.74.

Shareholding

Insiders

1.06%

Institutions

69.90%

Largest institutional holders

Fund	Stake
Redmile Group, LLC	10.74%
BlackRock Inc	6.09%
Vanguard Portfolio Management, LLC	3.79%
Vanguard Capital Management, LLC	3.71%
Acadian Asset Management LLC	3.63%
AQR Capital Management LLC	3.20%
Two Sigma Investments LLC	3.00%
Johnson & Johnson	2.82%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fate Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.